Results 11 to 20 of about 12,955 (195)
Circulation, 2010 Cachexia in chronic heart failure (HF) is a major clinical problem that is still underestimated for its impact on morbidity, mortality, and healthcare expenditures. The pathophysiology of cardiac cachexia is characterized by a catabolic/anabolic imbalance.
Springer, Jochen +2 more
openaire +2 more sources
Biomolecules, 2020 Alongside in vivo models, a simpler and more mechanistic approach is required to study the effects of myostatin on skeletal muscle because myostatin is an important negative regulator of muscle size.
Juulia H. Lautaoja +5 more
doaj +1 more source
Serum myostatin is reduced in individuals with metabolic syndrome. [PDF]
PLoS ONE, 2014 Myostatin is a negative regulator of skeletal muscle mass and may also modulate energy metabolism secondarily. We aim to investigate the relationship between serum myostatin and the metabolic variables in diabetic (DM) and non-diabetic subjects.A cross ...
Der-Sheng Han +7 more
doaj +1 more source
Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients. [PDF]
PLoS ONE, 2013 BACKGROUND: Myostatin is a muscle derived factor that functions as a negative regulator of skeletal muscle growth. Induction of myostatin expression was observed in rodent models of muscle wasting and in cachectic patients with cancer or pulmonary ...
Astrid Breitbart +13 more
doaj +1 more source
Indonesian Biomedical Journal, 2019 BACKGROUND: Sarcopenia is defined as a decrease in muscle mass accompanied by a decrease in muscle strength and performance. Sarcopenia arises from the disruption of the complex balance between anabolic and catabolic factors.
I Gusti Putu Suka Aryana +7 more
doaj +1 more source
Les Cahiers de Myologie, 2016 L’unique modele murin reproduisant la myopathie centronucleaire autosomique dominante associe a une mutation du gene dynamine -2 (KI-dnm2 R465W/+ ) reproduit la plupart des signes cliniques observes chez l’Homme, notamment une atrophie et une perte de force musculaire.
David Arnould, Anne-Cécile Durieux
openaire +1 more source
Low Myostatin Serum Levels Are Associated with Poor Outcome in Critically Ill Patients
Diagnostics, 2020 Background: Growth differentiation factor 8, GDF-8 (Myostatin), is a protein released by myocytes inhibiting muscle growth and differentiation. Serum concentrations of Myostatin can predict poor survival in different chronic diseases, but its role in ...
Theresa H. Wirtz +12 more
doaj +1 more source
FHL1 activates myostatin signalling in skeletal muscle and promotes atrophy
FEBS Open Bio, 2015 Myostatin is a TGFβ family ligand that reduces muscle mass. In cancer cells, TGFβ signalling is increased by the protein FHL1. Consequently, FHL1 may promote signalling by myostatin. We therefore tested the ability of FHL1 to regulate myostatin function.
Jen Y. Lee +3 more
doaj +1 more source
Frontiers in Pharmacology, 2020 Myostatin is a crucial cytokine that is widely present in skeletal muscle and that negatively regulates the growth and development of muscle cells. Recent research has shown that myostatin might play an essential role in bone metabolism.
Xin Zhi +10 more
doaj +1 more source
Critical Care, 2022 Background The objective was to investigate the role of gene expression and plasma levels of the muscular protein myostatin in intensive care unit-acquired weakness (ICUAW).
Julius J. Grunow +12 more
doaj +1 more source